January 2024 We are thrilled to announce that Schlich has again been recommended as a leading patent firm in the 2024 Juve rankings.
Schlich is one of just 25 firms to be recommended. We have been chosen for our work in the Pharma and Biotechnology, Medical Technology fields of expertise, as well as our work in EPO Oppositions.
In the ranking, company founder, George Schlich, was picked out as a recommended individual. He reacted: “This recognises the work of the whole firm, and we are pleased to be listed again”.
The Schlich attorneys have been recognised for work on patent filings for some of our significant clients, including AbbVie, Intellia Therapeutics, Fred Hutchinson Cancer Center, ONK Therapeutics, Nanofilm, NexaBiome, Rolls Royce and Vector Vitale, as well as a number of US universities.
Our work in oppositions before the EPO was also highlighted, with notable mentions made tof proceedings conducted on behalf of Intellia Therapeutics in the opposition proceedings over CRISPR-Cas patents against The Broad Institute, Sigma-Aldrich and Toolgen, together with our representation of Glenmark against Amgen regarding the formulation of Cinacalcet.
We are delighted to have been listed among the UK’s top patent firms and will endeavour to continue to strive for success in 2024 and beyond!
